Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis
Authors
Keywords
-
Journal
Journal of Comparative Effectiveness Research
Volume 11, Issue 3, Pages 203-212
Publisher
Future Medicine Ltd
Online
2022-01-13
DOI
10.2217/cer-2021-0134
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
- (2021) Preeti Kanikarla Marie et al. CLINICAL CANCER RESEARCH
- Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions
- (2020) Malek Kreidieh et al. Biomed Research International
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
- (2020) Eric X. Chen et al. JAMA Oncology
- Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy
- (2020) Marc T Roth et al. Expert Review of Anticancer Therapy
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy
- (2019) Arash Salmaninejad et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
- (2019) Jiajing Cai et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).
- (2019) Joleen Marie Hubbard et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer
- (2019) Michael A. Morse et al. ONCOLOGIST
- Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
- (2019) NaNa Keum et al. Nature Reviews Gastroenterology & Hepatology
- Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
- (2019) Michael A. Morse et al. ONCOLOGIST
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Colorectal cancer
- (2019) Evelien Dekker et al. LANCET
- Promising New Agents for Colorectal Cancer
- (2018) Satya Das et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Results and challenges of immune checkpoint inhibitors in colorectal cancer
- (2018) Sheik Emambux et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Nivolumab for the treatment of colorectal cancer
- (2018) Kortnye Maureen Smith et al. Expert Review of Anticancer Therapy
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.
- (2018) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- Current status of immunotherapy in metastatic colorectal cancer
- (2018) Pawel Wrobel et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
- (2018) Neda Yaghoubi et al. BIOMEDICINE & PHARMACOTHERAPY
- Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
- (2017) Van K Morris et al. LANCET ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Obesity and colorectal cancer: molecular features of adipose tissue
- (2016) Javier Martinez-Useros et al. Journal of Translational Medicine
- Immunotherapy of melanoma: Present options and future promises
- (2015) Anand Rotte et al. CANCER AND METASTASIS REVIEWS
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
- (2015) Yanping Xiao et al. Cancer Discovery
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
- Treatment in advanced colorectal cancer: what, when and how?
- (2009) I Chau et al. BRITISH JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis
- (2008) William M. Grady et al. GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started